Preview

Нефрология

Расширенный поиск

ИНГИБИЦИЯ РЕНИН-АНГИОТЕНЗИН-АЛЬДОСТЕРОНОВОЙ СИСТЕМЫ И НЕФРОПРОТЕКЦИЯ

https://doi.org/10.24884/1561-6274-2011-15-2-30-42

Полный текст:

Аннотация

В обзоре на основании анализа мультицентровых исследований обсуждаются механизмы нефро и кардиопротекции ингибиторами ангиотезин Iпревращающего фермента (ИАПФ) и блокаторами рецепторов ангиотензина (БРА), применение которых для лечения кардиологических больных и пациентов с диабетической и недиабетической нефропатиями постоянно увеличивается. Очерчены ситуации, при которых назначение блокаторов ренинангиотензинальдостероновой
системы (РААС) малоперспективно. У пожилых больных с высоким сердечнососудистым риском применение ИАПФ и БРА, особенно в сочетанном варианте, чревато развитием серьезных осложнений, включая ухудшение функции почек.

Об авторах

В. М. ЕРМОЛЕНКО
Российская медицинская академия последипломного образования
Россия
Кафедра нефрологии и гемодиализа


Н. Н. ФИЛАТОВА
Российская медицинская академия последипломного образования
Россия
Кафедра нефрологии и гемодиализа


А. Ю. НИКОЛАЕВ
Российская медицинская академия последипломного образования
Россия
Кафедра нефрологии и гемодиализа


Список литературы

1. Levitan D, Massry SG, Romoff M, Campese VM. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine. Nephron 1984; 36: 24-29

2. Лифшиц НЛ, Кутырина ИМ. Роль ренин-ангиотензи-новой системы в патогенезе артериальной гипертензии при хронической почечной недостаточности. Тер архив 1998; (6): 64-67

3. Карабаева АЖ, Смирнов АВ, Каюков И Г, Есаян АМ. Ренин-ангиотензин-альдостероновая система при хронической болезни почек. Нефрология 2006; (3): 43-48

4. Lonn ЕM, Yusuf S, Jha Р et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascu1ar protection. Circulation 1994; 90: 2056-2069

5. Dzau V, Berustein K, Celermaier D et al. The relevance of fissure angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardial 2001; 88 [Suppl 1]: 1-20

6. Stier Jr C T, Chander PN, Rocha R et al. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10(2): 97-107

7. Volpe M, Savoia C, De Paolis P et al. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002; 13 [Suppl. 3]: S173-S178

8. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16: 104-107

9. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128

10. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991

11. Russo LM, Osicka TM, Bonnet F et al. Albuminuria in Hypertension is linked to altered lysosomal activity and TGF-beta1 expression. Hypertension 2002; 39: 281-286

12. Pals D T, Masucci FD, Sipos F, Denning GS. A specific competitive antagonist of the vascular action of angiotensin II. Cirs Res 1971; 29: 664-672

13. Kang PM, Landau AJ, Eberhardt R T, Fishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127: 1388-1401

14. Ondetti MA, Williams NJ, Sabo EF et al. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 1971; 10: 4033-4039

15. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196: 441-444

16. Taguma Y, Kitamomot YK, Futaki G et al. Effect of captopril on heavy proteinuria in azotemic diabetes. N Engl J Med 1985; 313: 1617-1620

17. Bjorck S, Nyberg G, Mulec H et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 471-474

18. Lewis EJ, Hunsicker LG, Bain R P, Rohde RD. The effect of angiotensin-converting enzyme inhibitors on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462

19. Coronel F, Hortal L, Naranjo P et al. Captopril, proteinuria and peritoneal protein leakage in diabetic patients. Nephron 1989; 51: 443

20. Parving HH, Hommel E, Damkjaer Nielsen M, Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989; 299: 533-536

21. Ravid M, Lang R, Rachmani R, Lishner M. Long-term nephroprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependint diabetus mellitus. 7-year follow-up study. Arch Intern Med 1996; 156: 286-289

22. Ruilope LM. Renoprotection and rennin-angiotensin system blockade in diabetes mellitus. Am J Hypertens 1997; 10: 325-331

23. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; 1: 1190-1192

24. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria predicts cardiovascular disease in non-diabetic subjects. Lancet 1988; 2: 530-533

25. Ruilope LM, Alcazar JM, Rodicio JL. Renal consequences of arterial hypertension. J Hypertens 1992; 10

26. Hakim R, Goldszer RC, Brenner BM. Hypertension and proteinuria: Long term sequela and uninephrectomy in humans. Kidney Int 1984; 25: 930-936

27. Coppo R, Amore A, Roccatello D et al. Microalbuminuria in single kidney patients: relationship with protein intake. Clin Nephrol 1988; 29 (5): 219-228

28. Нанчикеева МЛ, Козловская ЛВ, Фомин ВВ и др. Эндотелиальная дисфункция и ремоделирование внутрипочечных сосудов как основа формирования гипертонической нефропатии. Ультразвуковая и функциональная диагностика 2009; (5): 84-94

29. Ruggenenti P, Perna A, Ganeva M et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17: 3472-3481

30. Shinosaki T, Miyai I, Nomura Y et al. Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis. Nephron 2002; 91 (4): 719-729

31. Buemi M, Allegra A, Corica F et al. Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 1999; 65 (6): 649-652

32. The EUCLID Study Group. Randomised placebocontrolled trial of lisinopril in normotensive patients with insulindependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792

33. Morelli E, Loon N, Meye TW et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39 (1): 76-82

34. Медведева ТЮ. Влияние препаратов, блокирующих ренин-ангиотензиновую систему, на прогрессирование почечной недостаточности в клинике и эксперименте. Автореф. дис.... канд. мед. наук. М., 2001

35. Gerstein HC, Mann J F, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426

36. Mann J F, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann intern Med 2001; 134: 629-636

37. Marre M, Lievre M, Chatellier G et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328: 495-498

38. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent End-stage Renal Disease: when to start and why possibly never stop: a post-hoc analysis of the REIN trial results. J Am Soc Nephrol 2001; 12: 2832-2837

39. Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860

40. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.

41. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20: 1625-1631

42. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578

43. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869

44. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309-2320

45. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678

46. Ibsen H, Olsen MH, Wachtell K et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Hypertension 2005; 45: 198-202

47. Цветкова ОА, Мустафина МХ. Органопротективные возможности и безопасность блокаторов рецепторов ангиотензина II. РМЖ 2009; 17 (8): 600-606

48. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252

49. Maschio G, Alberti D, Locatelli F et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999; 33 [Suppl 1]: S16-S20

50. Casas J P, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033

51. Hou F F, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140

52. Catapano F, Chiodini P, Nicola LD et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008; 52: 475-485

53. Jennings DL, Kalus JS, Coleman CI et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007; 24: 486-493

54. Bakris GL, Ruilope L, Locatelli F et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72: 879-885

55. Kunz R, Friedrich C, Wolbers M, Mann J F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48

56. Agodoa LY, Appel L., Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728

57. Matos J, de Lourdes Rodriguez M, Ismerim V et al. Effects of dual blockade of the renin angiotensin system inhypertensive type 2 diabetic patients with nephropathy. Clin Nephrol 2005; 64: 180-189

58. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100

59. Andersen NH, Poulsen PL, Knudsen ST et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. The CALM II study. Diabetes Care 2005; 28: 273-277

60. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572

61. Nakao M, Yoshimura A, Morita M et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117-124

62. Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary Artery disease Investigators. Lancet 2003; 362: 782-788

63. Ceconi С, Fох КM, Remme WJ et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINEN. Cardiovasc Res 2007; 73 (1): 237-246

64. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effect of ramipril on cardiovascular and microvascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259

65. Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atheroscle-rosis: principal results of PHYLLIS -a randomized double-blind trial. Stroke 2004; 35: 2807-2812

66. Borhani N, Mercuri M, Borhani P et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785-791

67. Zanchetti A, Rose E, Dal Palo C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-1676

68. Zanchetti A, Bond MG, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427

69. Lisowska A, Musial W. Heart failure in patients with chronic kidney disease. Rocz Akad Med Bialymst 2004; 49: 162-165

70. Berger AK, Duval S, Manske C et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153: 1064-1073

71. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр). Кардиоваскулярная терапия и профилактика 2008; 7 (6) (приложение 2): 1-30

72. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 [Suppl 1]: S1-S290

73. Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693-704

74. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906

75. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in Hypertension. Hypertension 2005; 45: 880-886

76. MacKinnon M, Shurraw S, Akbari A et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8-20

77. Esteban V, Gallego-Delgado Y, Lazaro A et al. Long-term treatment with an ACE inhibitor or an AT1 antagonist avoids hypertension-induced inflammation in the kidney. J Nephrol 2006; 19: 725-731

78. Татарский БА, Казенова НВ, Серебряков НВ. Прямой локатор ренина при лечении пароксизмальной формы фибрилляции предсердий. Артериальная гипертензия 2010; 16 (1): 74-81

79. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008; 15: 36-43

80. Della Chiesa A, Pfiffner D, Meier B, Hess OM. Sexual activity in hypertensive man. J Hum Hypertens 2003; 17 (8): 515-521

81. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Pressure 2003; 12 [Suppl 2]: 29-34

82. Serebruany V, Popov A, Malinin A et al. Valsartan inhibits platelet activity in different doses in mild to moderate hypertension. Valsartan Inhibits Plateled (VIP) trial. Am Heart J 2006; 151: 92-99

83. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48 (1): 73-79

84. Cole BK, Keller SR, Wu R et al. Valsartan protects pancreatic islets and adipose tissue from inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010; 55 (3): 715-721

85. Ha T-S, Lee J-S, Hong E-J. Delay of renal progression in methylmalonic acidemia using angiotensin II inhibition: a case report. J Nephrol 2008; 21: 793-796

86. Melis D, Parenti G, Gatti R et al. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin Endocrinol 2005; 63: 19-25

87. Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blockers in patients with lupus nephritis. J Int Med Res 2009; 37 (3): 892-898

88. Chen S, Ge Y, Si J et al. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008; 74 (9): 1128-1138

89. Kjeldsen SE, McInnes G T, Mancia G et al. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Blood Press 2008; 17: 170-177

90. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439

91. Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886

92. Schrader J, Luders S, Kulschewski A et al. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699-1703

93. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003; 60: 191-196

94. Mak I T, Freedman AM, Dickens B F, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40(9): 2169-2175

95. Pasini A F, Garbin U, Uava MC et al. Effect of sulfhydryl and non-sulfhydril angiotensin-converting enzyme inhibitors in endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443-450

96. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulfhydryl angiotensin convesting enzyme inhibitor zofenopril. J Int Med Res 2005; 33: 42-54

97. Mortensen EM, Restrepo M, Copeland L et al. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007; 27 (12): 1619-1626

98. Etminan M, Zhang B, Fitzgerald M, Brophy JM. Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-cohort study. Pharmacotherapy 2006; 26: 476-482

99. Hay U, Ludvik B, Gisinger Ch, Schernthaner G. Fehlender Effekt der ACE-Inhibition auf die Makroproteinurie bei diabetischer Nephropathie -eine Langzeitstudie fiber 6 Monate. Schw Med Wochenschr 1988; 118 (5): 165-169

100. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031

101. Niepen Patricia Van der, Woestenburg A, Brie H, et al. Effectiveness of Valsartan for Treatment of Hypertension: Patient Profiling and Hierarchical Modeling of Determinants and Outcomes (the PREVIEW Study). Ann Pharmacotherapy; 43 (5): 849-861

102. Solomon SD, Rice MM, Jablonski KA et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial. Circulation 2006; 114: 26-31

103. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222

104. Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-458

105. Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (8): 936-946

106. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcome in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blоcker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997

107. Suissa S, Hutchinson T, Brophy J et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919

108. Kent DM, Jafar TH, Hayward RA et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18 (6): 1959-1965

109. Mann J F, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553

110. Onuigbo MA, Onuigbo N T. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. Ren Fail 2008; 30 (1): 67-72

111. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006; 1:1054-1065

112. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535

113. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87

114. Giatras I, Lau J, Levey AS. Angiotensin-converting-enzyme inhibition and progressive renal disease study group. Effects of angiotensin-converting enzyme inhibits on the progression of nondiabetic renal disease: meta-analysis of randomised trials. Ann Intern Med 1997; 127: 337-345

115. Strippoli GFM, Craig M, Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828

116. Haynes R, Mason Ph, Rahimi K, Landray M. Dual blockade of the renin-angiotensin system: are two better than one? NDT 2009; 24: 3602-3607

117. Staessen JA, Wang J. Do ancillary properties of antihypertensive drugs explain the outcome results of recent trials? J Nephrol 2002; 15: 422-427

118. Phillips CO, Kashani A, Ko DK et al. Adverse effects of combination of angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930-1936

119. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559

120. Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369

121. Centers for Disease Control and Prevention (CDC): Prevalence of chronic kidney disease and associated risk factors -United States, 1999-2004. Morb Mortal Wkly Rep 2007; 56: 161-165

122. Centers for Disease Control and Prevention (CDC): Hospitalization discharge diagnoses for kidney disease -United States, 1980-2005. Morb Mortal Wkly Rep 2008; 57: 309-312

123. Epstein M. Re-examination RAS-blocking treatment regimens for abrogating progression of chronic kidney disease. Nat Clin Pract Nephrol 2009; 5: 12-13

124. Ruggenenti P, Remuzzi G. Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009; 5: 436-437

125. Abutaleb N. ONTARGET should not be over interpreted. NDT 2010; 25 (1): 44-47

126. Di Bari M, van de Poll-Franse L, Onder G et al. Antihypertensive medications and differences in muscle mass in older persons: the health, aging and body composition study. J Am Geriatr Soc 2004; 52: 961-996

127. Tobili JE, Stella I, Mazza ON et al. The effect of different anti hypertensive drugs on cavernous tissue in experimental chronic renal insufficiency. J Nephrol 2006; 19 (4): 419-428

128. Onuigbo M, Onuigbo N. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40: 233-239

129. Loriga G, Vidili G, Ruggenenti P et al. Renal hemodynamics and renoprotection. Nephron Clin Pract 2008; 110: 213-219

130. Ogata C, Kamide K, Suzuki Y et al. Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade. Clin Nephrol 2005; 64: 352-357

131. Sozen AB, Kayacan MS, Tansel T et al. Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. J internat Med Res 2009; 37: 996-1002

132. Ahmed A, Kamath N, Kossi M, Nahas A. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. NDT 2010; 25: 3977-3982

133. Адашева ТВ, Задионченко ВС, Павлов СВ и др. Органопротективные и плейотропные эффекты амлодипина у больных артериальной гипертензией и обструктивной болезнью легких. Сердце 2010; 9 (3): 165-171

134. Арутюнов ГП, Оганегзова Л Г. Антагонисты кальциевых каналов и нефропротекция. Сердце: журнал для практикующих врачей 2010; 9 (3): 160-164

135. Derwa A, Peeters P, Vanholder R. Calcium Channel blockers in the prevention of end-stage renal disease: a review. Acta clinica belgica 2004; 59 (1): 44-56

136. Peng T, Hu Z, Xia Q et al. A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria. Arzneimittelforschung 2009; 59 (12): 647-650

137. Renke M, Tylicki L, Rutkowski P et al. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease -placebo controlled, randomized, cross-over study. Acta Biochim Pol 2010; 57 (1): 119-123

138. Kaysen GA, Gambertoglio J, Jimenez I et al. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986; 29: 572-577

139. Gansevoort RT, de Zeeuw D, de Jong PR. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995; 10: 497-504

140. Sarafidis PA, Stafylas PC, Georgianos PI et al. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis. Am J Kidney Dis 2010; 55: 853-847

141. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. NDT 2004; 19 (6): 1354-1357

142. Orth SR, Schroeder T., Ritz E. Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. NDT 2005; 20: 2414-2419

143. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor-в1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 13-15

144. Kushiro T, Itakura H, Abo Y et al. Aliskiren, a novel oral renin inhibitor provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005

145. Parving HH, Persson F, Lewis JB, Hollenberg NK. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446


Для цитирования:


ЕРМОЛЕНКО В.М., ФИЛАТОВА Н.Н., НИКОЛАЕВ А.Ю. ИНГИБИЦИЯ РЕНИН-АНГИОТЕНЗИН-АЛЬДОСТЕРОНОВОЙ СИСТЕМЫ И НЕФРОПРОТЕКЦИЯ. Нефрология. 2011;15(2):30-42. https://doi.org/10.24884/1561-6274-2011-15-2-30-42

For citation:


ERMOLENKO V.M., FILATOVA N.N., NIKOLAEV A.Y. INHIBITION OF RENNIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND NEPHROPROTECTION. Nephrology (Saint-Petersburg). 2011;15(2):30-42. (In Russ.) https://doi.org/10.24884/1561-6274-2011-15-2-30-42

Просмотров: 26


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)